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A growing body of evidence suggests that the aggregation
and toxic potentials of amyloidogenic proteins, including
amyloid β-protein (Aβ), α-synuclein, and prion protein,
emerge through the interaction of these proteins with
neuronal and/or glial membranes. The aggregation and
deposition of Aβ are the initial events of Alzheimer’s disease
(AD), and the toxicity of aggregated Aβ is the basis for
the neuronal loss in AD brains. Thus, the Aβ behavior on
neuronal membranes should be one of the critical issues to
beclariﬁedforourfurtherunderstandingofthepathogenesis
of AD and to develop therapeutic strategies. To accelerate
studies in this ﬁeld, we have invited original research articles
as well as review articles that will provide novel information
for our special issue.
The ﬁrst three papers of this special issue describe the
crucial involvement of lipid rafts, which are speciﬁc mem-
brane microdomains on the cell surface that are rich in sph-
ingolipids and cholesterol, in the production, aggregation,
and toxicities of Aβ. The subsequent three papers focus on
the gangliosides, which are the major constituent of lipid
rafts, particularly in terms of their role in the induction of
conformational changes of Aβ, leading to their aggregation
and emerging toxicities.
The next two articles address how Aβ causes neuronal
injury by showing the possibility of formation of amyloid
channelsintheneuronalmembranes,resultinginthedisrup-
tion of calcium homeostasis that is critical for the function
and survival of neurons, and the possibility of generation of
radicals. In regard to the Aβ toxicities, much attention has
beenpaidtotheargumentthattheaccumulationofAβinside
neurons may be the critical step. In this context, the next
two papers propose a mechanism by which Aβ enters the
neurons, which are followed by another two papers showing
how the internalized Aβ acts pathologically inside neurons,
emphasizing the possibility that the mitochondria may be a
target of intraneuronal Aβ.
A further argument for the possible interaction between
Aβ and neuronal membranes is presented in the next four
papers. In these papers, it is presented how Aβ aﬀects the
properties of neuronal membranes or, conversely, how the
alteration of membrane properties aﬀects the processing of
amyloid precursor protein (APP) leading to Aβ generation.
Note that the metabolism of neuronal lipids, particularly
sphingolipids and ceramide, can be regulated in association
with APP processing.
The ﬁnal paper of this special issue describes a fore-
sighted aspect of science and technology of nanochemistry
withrespecttothepathologicalproteinaggregation,whichis
likely based on the catalysts of membrane lipids, suggesting
an opportunity for developing novel nanomedicines and
nanodiagnostics for various amyloidoses.2 International Journal of Alzheimer’s Disease
Wealllookforwardtoseeingfurtherexpansionofstudies
in this ﬁeld in the near future.
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